AMED Amedeo Res

RNS No 3285c
CHIROSCIENCE GROUP PLC
1st March 1999                                      
                                      
                   CHIROCAINE DESIGNATED APPROVABLE BY FDA
                                      
                                      
Chiroscience  Group plc announces today that it has received  an  Approvable
Letter  from  the  United  States  Food and Drug  Administration  (FDA)  for
Chirocaine,  its  long-acting  local  anaesthetic.   The  Approvable  Letter
represents  the last step in the regulatory process before FDA  approval  of
the  New  Drug Application. The Company is in advanced discussions with  the
FDA regarding final printed labeling.
 
Dr John Padfield, Chief Executive of Chiroscience Group plc, commented:
 
"This important decision is consistent with Chiroscience's belief that,
following the final FDA review of the product labeling and approval of its
New Drug Application, Chirocaine will be regarded as an important addition
to the range of drugs used in anaesthesia and pain."
 
This document is intended to provide information on Chiroscience to
interested members of the public and not to provide product information to
health professionals.
 
For further information contact:

Dr John Padfield, Chief Executive    Giles Sanderson
Chiroscience Group plc               Victoria Springett
Tel: +44 (0)1223 420430              Financial Dynamics
http://www.chiroscience.com          Tel: +44 (0)171 831 3113
                                     
Chiroscience Group plc
Chiroscience  is an emerging pharmaceutical company which uses  its  diverse
technology platform to discover, develop and bring to market novel medicines
for  improved  healthcare.   It  has  three  businesses:  Chiroscience  R&D,
Rapigene and ChiroTech.
 
Chiroscience R&D's focus is on innovative small molecule drugs  and  related
diagnostics  in  the  therapeutic  areas  of  inflammatory  disease,   pain,
osteoporosis,  cancer  and  autoimmune diseases.   Its  technology  platform
allows   the  conception  and  development  of  receptor-based  and  enzyme-
inhibiting  small molecule drugs with high selectivity of action.   Rapigene
is  involved  in  the  creation and provision of  genomic  technologies  and
services   to  partner  companies  and  to  Chiroscience's  drug   discovery
programmes.   Its  DNA analysis systems comprise of DNA  hybridization,  DNA
arrays  and  mass  spectrometry tags. ChiroTech provides  chiral  technology
services  to  pharmaceutical and related industries, including  Chiroscience
R&D.
 
Chiroscience Group plc is listed on the London Stock Exchange and  is  based
in Cambridge and Stevenage, UK, and Seattle, Washington, USA.
 
Chiroscience  financial  highlights for the six months  to  31  August  1998
(unaudited):

+   Revenues  increased to #11.4m (H1 1997: #9.2m); net loss for the  period
#11.4m (H1 1997: #14.4m)

+   ChiroTech  contributed sales of #6.8m (H1 1997:  #5.9m);  Chiroscience's
drug discovery business contributed revenues of #4.5m (H1 1997: #3.3m).

+  Investment in research and development of #13.5m (1H 1997: #19.0m).

+  Current cash reserves of #59m as at 24 September 1998.
 
 
 
END

MSCAILVAVLILIAA

Grafico Azioni Amedeo Res (LSE:AMED)
Storico
Da Giu 2024 a Lug 2024

Grafico Azioni Amedeo Res (LSE:AMED)
Storico
Da Lug 2023 a Lug 2024